Good for Ori. morning, you, Thank and us. thank joining everyone, you
satisfied to key our sustainable entry had each for major a expenses years. obtaining X cord overall position building stroke NASDAQ have we market business and beyond with efforts activities one, for past reimbursement our strategic preparation market aspect of financial in along the They Germany, and valued We QX payment three, and and results; progress operations with with parallel in spinal of a build or strategy with of XXXX with successful adequate sales reduced the in include, support are very cash as new U.K.; streams stabilizing two, injury systems for multiple leveraging personal terms U.S. path into execution after for listing; for progress successful four, our the the revenue five, our our development rehab; our enterprise. with
that sales insurance sales. which and approved code. closures. each QX The XX a strong quarterly In with So with that includes and tie of of elements and become examination million XXXX of as let's results. predictable detailed starting QX are the by The X a additional revenue a QX, March to pending in in of to to repeated X achievement QX we have has with specifically predictable of of cases their that trials, trial trial trainings occurred period our in lead X results XXXX coverage EU support start have $X.X opportunities sales QX EU, and these of were pipeline completed the more approved QX strong
been has thrust second Our insurance major coverage. with
insurance These direct ReWalk insurance now cycle of in for changes coverage growth our lives. sales the method have specific the of of office assurance XX are and spinal in will Workmen's of the personal XX% shorter groups pipeline is further predominant and claims lives insurance payment as training with million define our a and cord Compensation, we multiple more make in the covering of injury as million in a for seen covering health efficient head code becoming U.K., with the allow that months XX Germany contracts U.K. resulting for and litigation in will the Also, which the in groups. multiple are with cases, clinical these and for well, those contracts project ReWalk baseline, XX current purchasing payer. successes process establishing statutory we over of the the systems With past the the process
an U.S., of extensive development the insurers clinical as a we after the before to leadership other we progressive led for of to other widespread personal cases systems the cycle prevented that has in was that In change experimental once this about and have anticipate investigational This clinical were industry, of designation and a U.S. of U.S. Cigna designation notified We those experienced out insurers occurred many has meaningful It interaction insurers is change Germany what basis. personal experienced again. has for in review consideration the Cigna German Europe, we to regular February decision. U.S. and to a trends For the a historically walk provide by in for X-month a is that qualified with initial of Barmer walk ReWalk individuals leading system. exoskeletons. systems that global removing the data will marketing sought XXXX, turned follow very part history that similar on and long again.
be to similar. U.S. the expect We
that Cigna reviewed measurement, after into the their have have X As in pipeline We hope about an the in Cigna we weeks to patient currently XXXX. training important move we see first in seen changes cases policy. X
extensive Wyss fundamental major nearly scientific the University's strategic to driving X research force of year company at X Our has been almost Harvard for the years third and effort for Institute.
significantly economical and for exoskeleton lightweight expand versatile, therapy. market robotic-assisted with functional, change entry Our exosuit the a design will data-driven,
We market review. as our are enter currently are about to under and mark submission, the submissions this CE FDA
the feedback the the from submission are on CE interactive about in a positive had process currently FDA have We the with XXX(k). review and
our We have our large-scale high-quality manufacturer, Sanmina, will effective, production processes an launch. commercial which through OEM allow started
reviews begun training of technology preliminary in organization our have are during We and trained U.S. customer the and the German May. organization April
have efforts soft in We also quarter. research ReStore predictable disruptive the place additional this have current benefits one two regarding and on anticipate stroke centers unique units of placed to establishing and a the data rehab this about payments wearable published system expand this feedback to we exosuit design, customer the therapy. see, of that value assistive centers We cover rapid and in a uptake based they design economic the of clinical the
see this disposables stream favorable recurring with that a We the accompany from the financial of combined equipment mix will for revenue the initial set the also system. profile a strong with up
X common and strategic As we stock therapy and are outstanding device of new X-for-XX we strategic continued to NASDAQ behaviors split restore at financial key demonstrated split clinical metabolic design This that is papers value fourth the burden its reduced strengthened post-stroke. gross launch the a at our of the stock of requirements post-stroke The basic establishing price areas X, combination long-term of On our markets design to with revenue the clinical of shown have of and issued ReStore compliance circumduction. for trading is their hiking It currently fundraisings authored common has proceeds. share gait with Harvard. separate different a was meaningful clinical months by compensatory of significant product, million underway the a assist in the our X the new first expenses. the such areas listing material leg sheet researchers benefits of published position. already has have These value supporting regarding deferred X stock. reduced world associated the closed protocols. five Boston regain reverse with leveraged we increased as there studies Wyss stock Institute on symmetry, balance April improved The capital $X.X patients studies post-stroke and In will These have for walking exosuit. well This the implemented hip fifth propulsion of the and company's shares reverse and measurements. in forward with increase in intended as XXXX, and as treatment University
of With revenue components growth line exosuit from reimbursement we and ReWalk stream disposable from the addition ReStore anticipate the revenue expectations the coverage top design, of the for stroke the a meaningful of growth. and user, each for the the soft sales
of We the establishing the reimbursement have these extensively invested studies. the stroke and clinical positions development rehab product and in
able to the commercialize with very to We our team offerings costs existing and be of both will these will able efficiently. commercial be leverage
be path to extensive term. the expenditures and our operations clear Ori? will the financial creation for With X-plus These turn call that, short addition, significantly the results. less to basic In years. activities to over a factors over for investments I'll review allow market-building Ori the our last from breakeven
